Aug 31, 2026 08:32AM
Aug 31, 2026 08:30AM
Aug 12, 2026 04:05PM
Aug 5, 2026 08:30AM
Aug 5, 2026 08:30AM
Jul 21, 2026 04:30PM
May 21, 2026 07:30AM Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
May 15, 2026 04:00PM
May 13, 2026 04:10PM
May 13, 2026 04:10PM
Apr 17, 2026 04:00PM
Apr 17, 2026 04:00PM
Apr 15, 2026 04:05PM
Mar 19, 2026 07:21AM Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Mar 17, 2026 05:54PM
Mar 2, 2026 03:39PM
Feb 24, 2026 08:00AM
Feb 23, 2026 08:00AM
Feb 18, 2026 08:00AM
Feb 17, 2026 10:48AM
Jan 23, 2026 08:13AM Acrivon to present ACR-368 endometrial cancer data at ESGO congress
Jan 23, 2026 08:11AM
Jan 8, 2026 07:32AM
Jan 8, 2026 07:30AM
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM
Dec 17, 2025 09:34AM
Dec 17, 2025 09:34AM UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipelin
Dec 17, 2025 07:30AM
Dec 17, 2025 07:30AM
Nov 13, 2025 04:10PM
Oct 22, 2025 04:27PM
Oct 22, 2025 04:15PM
Oct 1, 2025 04:30PM
Aug 13, 2025 04:15PM Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
May 15, 2025 07:26AM
May 14, 2025 04:10PM
Apr 25, 2025 08:00AM
Apr 7, 2025 04:05PM
Apr 7, 2025 04:05PM
Mar 27, 2025 05:44PM
Mar 19, 2025 08:00AM Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Mar 19, 2025 08:00AM
Feb 5, 2025 08:00AM
Feb 5, 2025 08:00AM
Nov 13, 2024 07:00AM
Oct 17, 2024 08:00AM
Oct 16, 2024 04:00PM
Oct 11, 2024 08:03AM Acrivon Therapeutics (ACRV) Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Oct 11, 2024 08:00AM

329,909 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All